Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Maintenance immunotherapy fails to improve survival in extensive-stage small cell lung cancer (SCLC), according to late-breaking results from the CheckMate 451 study to be presented today at the European Lung Cancer Congress 2019.
PD-L1 expression levels were generally not a factor in Quality of Life
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC)
Results from patients enrolled in a phase I study and FDA expanded access programme presented at AACR 2019
Extended indication concerns treatment of male patients
Results from meta analysis of foecal metagenomes
New indication concern combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours
Change in one of the existing indications concerns combination therapy in adult patients with previously untreated multiple myeloma who are not eligible for transplant
New indication concerns treatment of adult patients with multiple myeloma in combination with bortezomib and dexamethasone after at least one prior regimen including lenalidomide
EMA published questions-and-answers document for patients, healthcare professionals and the general public
Insights from the patient-derived xenograft models of breast cancer in mice
Pertuzumab, with intravenous trastuzumab and chemotherapy, is recommended for the adjuvant treatment of HER2-positive early stage breast cancer in adults at high risk of recurrence
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
